Immunomedics (IMMU) 10-K2009 FY Annual report

Filed: 27 Aug 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: AACR, abnormal, activitiesin, ADCC, Affiliated, ahead, al, analog, Anderson, andinvivo, anemia, announced, antidilutive, Aranesp, arbitration, artery, ASCO, asserting, Banc, Bartholomew, BENLYSTA, Bioscience, Biotech, bortezomib, Carolina, categorization, categorized, CDC, cellular, Chancery, chapter, chart, ChiefFinancial, clarification, clivatuzumab, comparison, conference, consequential, coronary, Council, CSF, denied, depth, diabetic, dismal, downturn, easier, economy, England, epilepsy, fall, false, FDG, FINRA, fluorodeoxyglucose, foot, frontline, glucose, hearing, hematocrit, hierarchy, imperative, inappropriately, induced, inflamed, infrequently, input, intact, interferon, irinotecan, kidney, lenalidomide, Leung, London, melanoma, melphalan, metabolism, methionyl, mobilizing, modest, MRC, muscle, nonqualified, Ohio, online, orEITF, Park, PEGylated, Pfizer, platelet, pmol, poster, proliferation, prolonged, pronouncement, punitive, quantity, radiopharmaceutical, receptor, RECIST, recurring, red, relief, relieved, rescind, resistant, Roswell, sera, serologically, serum, Shawn, SinoMab, Sjogren, Skytech, SNM, sought, spite, St, staffing, stem, sugar, supervise, tetraxetan, thalidomide, thein, timeline, tort, transient, unadjusted, Uniform, unobservable, unreasonable, unresponsive, Vice, violated, visible, vitroand, widespread, yttrium

Removed: achieving, aggressive, ago, APB, applicant, assessable, assigned, Australia, authorizing, bear, begun, BILAG, biodistribution, Borrower, bound, Brigham, British, Bureau, calculation, centralized, chaperone, Chase, collateral, commenced, computer, concentration, confirm, consistent, controlling, convert, coordinated, cured, death, Debenture, deciding, declined, detachable, EMEA, escrow, expend, financed, Fleet, forty, Fox, GCP, GMP, indenture, injection, investigator, Isle, jaffe, JPMorgan, LYMPHOCIDE, LYMPHOSCAN, malignant, Marburg, marvin, medullary, MHC, monitor, MTC, mutual, NIH, optimal, optimize, originally, oversee, owner, Paying, permanent, pharmacokinetic, pharmacovigilance, principle, procedure, prospectively, randomized, range, rare, ratified, RBC, refinance, refine, reflected, Registrar, regulated, relapse, repay, repayment, repeatedly, requesting, resolution, retire, retirement, retrospectively, returned, revision, School, supplied, surgery, thyroid, training, undisclosed, validation, vigorously, virtue, voluntary, voted, women, writing

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IMMU similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Immunomedics. Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Annual Report on Form 10-K for the fiscal year ended June 30, 2009 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: August 27, 2009

/s/ CYNTHIA L. SULLIVAN

Cynthia L. Sullivan

President and Chief Executive Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.